Skip to main
STRO
STRO logo

STRO Stock Forecast & Price Target

STRO Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 23%
Hold 23%
Sell 8%
Strong Sell 0%

Bulls say

Sutro Biopharma Inc is advancing its portfolio of biopharmaceutical products, with preclinical data indicating significant improvements in anti-tumor activity and safety profiles for its candidates, such as STRO-004 and STRO-006. The company is optimizing its capital allocation through a substantial workforce reduction of approximately 50%, which is projected to cut operating expenses by 50-70% starting in Q2 2025, enhancing financial sustainability through 2026. The innovative design of their pipelines, particularly for the integrin β6 ADC, positions Sutro favorably against competitors, potentially unlocking superior therapeutic advantages in the oncology market.

Bears say

Sutro Biopharma has recently experienced significant headwinds, including a net loss of $227.4 million for FY24, equivalent to $2.96 per share, which raises concerns about its financial stability moving forward. The company's decision to undertake a near-50% reduction in headcount and discontinuation of the luvelta program reflects a strategic refocusing that may hinder its product pipeline and future revenue potential. Additionally, the risks associated with achieving clinical results, competitor advancements, and reimbursement challenges further compound the negative outlook on the company's financial performance and stock valuation.

STRO has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 23% recommend Buy, 23% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sutro Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sutro Biopharma Inc (STRO) Forecast

Analysts have given STRO a Buy based on their latest research and market trends.

According to 13 analysts, STRO has a Buy consensus rating as of Jul 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sutro Biopharma Inc (STRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.